Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Five Chinese Ministries Jointly Inspect Expanded National Immunization Program

This article was originally published in PharmAsia News

Executive Summary

China's Minitry of Health, National Development and Reform Commission, Ministry of Education, Ministry of Finance, and State FDA have decided to jointly inspect the expanded national immunization program across the country immediately. With emphasis on self-examination, the ministries will conduct timely spot checks on selected provinces. The focus is on increasing the implementation of the immunization program, including vaccine purchase and supply, application of new vaccines, establishment and operation of a cold chain system and inoculation service management. In addition, financial input and fund usage by the state and local governments, as well as formulation on compensation for preventing inoculation-caused adverse incidents, will be inspected. (Click here for more - Chinese Language)

You may also be interested in...

OTC Innovation In An Age Of Pandemics – Q&A With Stada’s New R&D Head Stephen Makin

COVID-19 has shifted consumer health behaviour towards prevention and general wellbeing. However, finding out what consumers actually want and need is still the essence of good OTC innovation, according to Stada Arzneimittel's new vice president of consumer healthcare product development Steve Makin.

Coronavirus Update: Novartis Joins Antiviral Therapies Search With Novel DARPin Alliance

Swiss biotech Molecular Partners will receive upfront payment of CHF 60m, including equity.

Experts Call For Unifying Measures For EU Political And Regulatory Oversight

Just as the MDR and IVDR are being implemented, increasing regulatory divergence in Europe is a growing danger to patient safety throughout the EU, not least through increasing costs and impacting device availability.




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts